Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07400653 Berobenatide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07400653 clinical trial report covering Berobenatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07403266 YCJ-01 Drug Resistant Epilepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07403266 clinical trial report covering YCJ-01, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260451 Nifuratel/Nystatin Trichomonas Vaginitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
CTR20260451 clinical trial report covering Nifuratel/Nystatin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260496 Orelabrutinib Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
CTR20260496 clinical trial report covering Orelabrutinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07400107 Zenagamtide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07400107 clinical trial report covering Zenagamtide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260491 Lidocaine/Prilocaine Premature Ejaculation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
CTR20260491 clinical trial report covering Lidocaine/Prilocaine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07404358 Dalargin Postoperative Complications Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07404358 clinical trial report covering Dalargin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20260366 Human immunoglobulin(Hualan Biological Engineering) Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
CTR20260366 clinical trial report covering Human immunoglobulin(Hualan Biological Engineering), Phase 3, endpoints, sponsor, geography, readout timing and
Latest Hotspot
8 min read
NCT07402759 Levocarnitine Oligoasthenozoospermia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07402759 clinical trial report covering Levocarnitine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07402876 Methotrexate Primary Vitreoretinal Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07402876 clinical trial report covering Methotrexate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07402512 Deuremidevir Hydrobromide Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07402512 clinical trial report covering Deuremidevir Hydrobromide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07407660 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07407660 clinical trial report covering Venetoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.